{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:56:28Z","timestamp":1789721788188,"version":"4.0.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,5,13]],"date-time":"2013-05-13T00:00:00Z","timestamp":1368403200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Sarcoma Res"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/2045-3329-3-8","type":"journal-article","created":{"date-parts":[[2013,5,13]],"date-time":"2013-05-13T16:24:42Z","timestamp":1368462282000},"source":"Crossref","is-referenced-by-count":41,"title":["Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib"],"prefix":"10.1186","volume":"3","author":[{"given":"Silvia","family":"Stacchiotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Crippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Pilotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Gronchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Y","family":"Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo G","family":"Casali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,5,13]]},"reference":[{"key":"43_CR1","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/jso.21835","volume":"103","author":"H Mankin","year":"2011","unstructured":"Mankin H, Trahan C, Hornicek F: Pigmented villonodular synovitis of joints. J Surg Oncol. 2011, 103: 386-389. 10.1002\/jso.21835","journal-title":"J Surg Oncol"},{"key":"43_CR2","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1093\/annonc\/mdn033","volume":"19","author":"JY Blay","year":"2008","unstructured":"Blay JY, El Sayadi H, Thiesse P: Complete response to imatinib in relapsing pigmented villonodular synovitis\/tenosynovial giant cell tumor (PVNS\/TGCT). Ann Oncol. 2008, 19: 821-822.","journal-title":"Ann Oncol"},{"key":"43_CR3","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1002\/cncr.26409","volume":"118","author":"PA Cassier","year":"2012","unstructured":"Cassier PA, Gelderblom H, Stacchiotti S: Efficacy of imatinib mesylate for the treatment of locally advanced and\/or metastatic tenosynovial giant cell tumor\/pigmented villonodular synovitis. Cancer. 2012, 118: 1649-1655. 10.1002\/cncr.26409","journal-title":"Cancer"},{"key":"43_CR4","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1073\/pnas.0507321103","volume":"103","author":"RB West","year":"2006","unstructured":"West RB, Rubin BP, Miller MA: A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci USA. 2006, 103: 690-695. 10.1073\/pnas.0507321103","journal-title":"Proc Natl Acad Sci USA"},{"key":"43_CR5","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1097\/PAS.0b013e31802b86f8","volume":"31","author":"JS Cupp","year":"2007","unstructured":"Cupp JS, Miller MA, Montgomery KD: Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides. Am J Surg Pathol. 2007, 31: 970-976. 10.1097\/PAS.0b013e31802b86f8","journal-title":"Am J Surg Pathol"},{"key":"43_CR6","doi-asserted-by":"crossref","unstructured":"Ray-Coquard I, Gelderblom H, Chevreau C: An open-label international multicentric phase II study of nilotinib in progressive pigmented villo-nodular synovitis (PVNS) not amenable to a conservative surgical treatment. J Clin Oncol. 2012, 30 (15 Suppl 1):","DOI":"10.1200\/jco.2012.30.15_suppl.10006"},{"key":"43_CR7","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/sj.leu.2404944","volume":"22","author":"N Brownlow","year":"2008","unstructured":"Brownlow N, Russell AE, Saravanapavan H: Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis. Leukemia. 2008, 22: 649-52. 10.1038\/sj.leu.2404944","journal-title":"Leukemia"},{"key":"43_CR8","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood.V92.12.4778","volume":"92","author":"C Menetrier-Caux","year":"1998","unstructured":"Menetrier-Caux C, Montmain G, Dieu MC: Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood. 1998, 92: 4778-91.","journal-title":"Blood"},{"key":"43_CR9","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1172\/JCI21102","volume":"114","author":"C Borg","year":"2004","unstructured":"Borg C, Terme M, Ta\u00efeb J: Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest. 2004, 114: 379-88.","journal-title":"J Clin Invest"},{"key":"43_CR10","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1158\/0008-5472.CAN-08-3807","volume":"69","author":"C M\u00e9nard","year":"2009","unstructured":"M\u00e9nard C, Blay JY, Borg C: Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res. 2009, 69: 3563-9. 10.1158\/0008-5472.CAN-08-3807","journal-title":"Cancer Res"},{"key":"43_CR11","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm.2429","volume":"17","author":"L Zitvogel","year":"2011","unstructured":"Zitvogel L, Kroemer G: Anticancer effect of imatinib via immunostimulation. Nat Med. 2011, 17: 1050-1. 10.1038\/nm.2429","journal-title":"Nat Med"}],"container-title":["Clinical Sarcoma Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2045-3329-3-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/2045-3329-3-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2045-3329-3-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,26]],"date-time":"2020-07-26T17:40:41Z","timestamp":1595785241000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalsarcomaresearch.biomedcentral.com\/articles\/10.1186\/2045-3329-3-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,13]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["43"],"URL":"https:\/\/doi.org\/10.1186\/2045-3329-3-8","relation":{},"ISSN":["2045-3329"],"issn-type":[{"value":"2045-3329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,13]]},"article-number":"8"}}